Generali Investments CEE investicni spolecnost a.s. Sells 6,982 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Generali Investments CEE investicni spolecnost a.s. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,468 shares of the biopharmaceutical company's stock after selling 6,982 shares during the period. Gilead Sciences comprises about 0.8% of Generali Investments CEE investicni spolecnost a.s.'s holdings, making the stock its 26th largest holding. Generali Investments CEE investicni spolecnost a.s.'s holdings in Gilead Sciences were worth $8,232,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in GILD. Bridgewater Associates LP raised its position in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its stake in shares of Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares during the period. Ontario Teachers Pension Plan Board raised its holdings in shares of Gilead Sciences by 54.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after acquiring an additional 13,086 shares in the last quarter. Mufg Securities Americas Inc. purchased a new stake in Gilead Sciences in the fourth quarter worth $1,699,000. Finally, Capital International Inc. CA boosted its holdings in Gilead Sciences by 23.8% in the fourth quarter. Capital International Inc. CA now owns 312,209 shares of the biopharmaceutical company's stock valued at $28,839,000 after acquiring an additional 60,035 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Oppenheimer cut their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Down 0.2%

GILD opened at $111.28 on Friday. The stock has a market capitalization of $138.42 billion, a price-to-earnings ratio of 23.43, a PEG ratio of 0.72 and a beta of 0.29. The firm has a 50 day moving average price of $107.02 and a 200-day moving average price of $103.93. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.32) EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date was Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares of the company's stock, valued at approximately $13,238,908.56. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the sale, the chief financial officer owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,500 shares of company stock worth $6,340,745. 0.27% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.